5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
1 citations
,
April 2024 in “Journal of Dermatological Science”
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
1 citations
,
October 2025 in “International Journal of Molecular Sciences” Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.
20 citations
,
December 2020 in “Frontiers in Immunology” The immune processes causing VKH and vitiligo are similar in dogs and humans.
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
October 2024 in “International journal of medicine and psychology.” Targeted immune modulation can help achieve stable remission in alopecia areata.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
New hair regrowth therapies show promise but need more research.
15 citations
,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
144 citations
,
September 2012 in “Genes & development” Aging causes skin stem cells to work less effectively.
15 citations
,
January 2023 in “Antioxidants” Oxidative stress plays a significant role in alopecia areata, and new treatments may include JAK inhibitors and antioxidants.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
5 citations
,
April 2022 in “Evidence-based Complementary and Alternative Medicine” Shaoyao Gancao decoction may treat alopecia areata by affecting the PI3K/AKT signaling pathway.
3 citations
,
October 2025 in “Biomedicines” New treatments for seborrheic dermatitis show promise for difficult cases.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
April 2026 in “International Journal of Drug Delivery Technology” Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
April 2026 in “Antibodies” The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
January 2026 in “Frontiers in Drug Discovery” Transforming skin disease treatment requires new strategies, better drug models, and patient-focused research.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
November 2025 in “FEBS Open Bio” JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.